Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Turnstone Biologics Corp.: Certificate of incorporation amended and restated in its entirety following merger.
- Change
- charter amendment
Exact text from the filing
(i) the Surviving Corporation’s certificate of incorporation was amended and restated in its entirety, as set forth in Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Turnstone Biologics Corp.: Bylaws of Merger Sub became the bylaws of the Surviving Corporation following merger.
- Change
- bylaw amendment
Exact text from the filing
(ii) the bylaws of Merger Sub as in effect immediately prior to the Effective Time became the bylaws of the Surviving Corporation, as set forth in Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Turnstone Biologics Corp. completed a disposition involving H. Lee Moffitt Cancer Center and Research Institute, Inc for total consideration of approximately $3.0 million to offset Turnstone’s obligations to Moffitt under the Alliance Agreement, of which, approximately $1.8 millio (closed 2025-08-11).
- Action
- disposition
- Counterparty
- H. Lee Moffitt Cancer Center and Research Institute, Inc
- Consideration
- total consideration of approximately $3.0 million to offset Turnstone’s obligations to Moffitt under the Alliance Agreement, of which, approximately $1.8 millio
- Closing
- 2025-08-11
Exact text from the filing
certain obligations of the Company’s under the Myst Merger Agreement (as defined in the Asset Purchase Agreement). Turnstone received a total consideration of approximately $3.0 million to offset Turnstone’s obligations to Moffitt under the Alliance Agreement (as defined in the Asset Purchase Agreement), of which, approximately $1.8 million was placed into an
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Turnstone Biologics Corp. underwent a change of control involving XOMA Royalty Corporation for per Share of (i) $0.34 cash plus (ii) one non-transferable contractual contingent value right (CVR) representing potential additional cash payments (closed 2025-08-11).
- Action
- change of control
- Counterparty
- XOMA Royalty Corporation
- Consideration
- per Share of (i) $0.34 cash plus (ii) one non-transferable contractual contingent value right (CVR) representing potential additional cash payments
- Closing
- 2025-08-11
Exact text from the filing
Purchaser completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “Shares”), for a price per Share of (i) $0.34 (the “Cash Amount”), payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right (“CVR”), which shall
View on SEC.gov